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INTRODUCTION
Staphylococcus aureus causes a range of potentially life-threatening 
infections including skin lesions,1 lung infections,2 bacteremia,3 ocu-
lar infections, and endocarditis.4 In 2009 alone, there were 697,248 
S. aureus associated hospitalizations, a full two-third of which were 
caused by methicillin-resistant S. aureus (MRSA).5 MRSA causes more 
than 11,000 deaths in the United States each year,6 and it is now com-
mon among both hospital-associated and  community-associated 
infections. A 2012 estimate puts the cost of community associ-
ated MRSA alone at $1–13 billion annually.7 In addition to the high 
clinical incidence of MRSA,8 S. aureus resistance to other antibiotics 
is on the rise.9 The enormous financial and human costs of drug-
resistant S. aureus infections has prompted both the CDC and 
WHO to highlight this threat and call for new treatment options.6,10 
However, technical constraints and economic concerns have sty-
mied  antibiotic development pipelines. Moreover, seven decades of 
experience has shown that bacterial pathogens begin developing 
resistance to new chemotherapies within a few years of their initial 
use.11 Therefore, addressing this medical need in a comprehensive 
fashion will require more careful antibiotic stewardship combined 
with a search for novel and more robust therapeutic agents.
As opposed to further elaboration of small molecule chemother-
apies, there is mounting evidence that bacteriolytic enzymes repre-
sent a powerful new class of antibacterial agents.12–14 Staphylococcus 
simulans lysostaphin (LST) is a highly effective, two-domain anti-
staphylococcal bacteriocin that efficiently kills both drug-sensitive 
and drug-resistant S. aureus. LST efficacy has been demonstrated 
in a wide range of in vitro studies, in vivo studies, and even human 
trials.15 Because of its own bacterial origins, however, LST drives a 
potent immune response in animals and humans. LST-antibody 
immune complexes are thought to cause toxicity in numerous mod-
els, including nonhuman primates.15 Thus, immunogenicity repre-
sents a serious barrier to LST clinical translation, and developing 
deimmunized variants would reduce associated health risks, facili-
tate clinical testing and approval, and ultimately enable repeated 
use in individuals requiring multiple treatment cycles.
To address the issue of LST immunogenicity, we sought to capi-
talize on a detailed understanding of cellular and molecular pro-
cesses that underlie development of antidrug antibodies. Immune 
surveillance of biotherapeutics begins with internalization of a 
protein drug by antigen-presenting cells. These cells process the 
protein into short peptide fragments, putative immunogenic 
sequences are bound by class II major histocompatibility complex 
proteins (MHC II, also known as HLA in humans), and the com-
plexes are trafficked to the cell surface where they are interrogated 
by CD4+ helper T cells.16 Bona fide immunogenic peptides, termed 
T cell epitopes, mediate formation of ternary MHC-peptide-T cell 
receptor complexes. The result of this cell–cell interaction is a 
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Staphylococcus aureus infections exert a tremendous burden on the health-care system, and the threat of drug-resistant strains 
continues to grow. The bacteriolytic enzyme lysostaphin is a potent antistaphylococcal agent with proven efficacy against both 
drug-sensitive and drug-resistant strains; however, the enzyme’s own bacterial origins cause undesirable immunogenicity and pose 
a barrier to clinical translation. Here, we deimmunized lysostaphin using a computationally guided process that optimizes sets of 
mutations to delete immunogenic T cell epitopes without disrupting protein function. In vitro analyses showed the methods to be 
both efficient and effective, producing seven different deimmunized designs exhibiting high function and reduced immunogenic 
potential. Two deimmunized candidates elicited greatly suppressed proliferative responses in splenocytes from humanized mice, 
while at the same time the variants maintained wild-type efficacy in a staphylococcal pneumonia model. Overall, the deimmunized 
enzymes represent promising leads in the battle against S. aureus.
Molecular Therapy — Methods & Clinical Development (2015) 2, 15021; doi:10.1038/mtm.2015.21; published online 17 June 2015
H.Z. and Y.C. contributed equally to this work.
1Thayer School of Engineering, Dartmouth, Hanover, New Hampshire, USA; 2Laboratory of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, People’s 
Republic of China; 3Department of Computer Science, Dartmouth, Hanover, New Hampshire, USA; 4Program in Experimental and Molecular Medicine, Dartmouth, Hanover, 
New Hampshire, USA; 5Department of Microbiology and Immunology, Dartmouth, Hanover, New Hampshire, USA; 6Institute for Immunology and Informatics, University of 
Rhode Island, Providence, Rhode Island, USA; 7Norris Cotton Cancer Center, Dartmouth, Hanover, New Hampshire, USA; 8Department of Biological Sciences, Dartmouth, Hanover, 
New Hampshire, USA. Correspondence: KE Griswold (karl.e.griswold@dartmouth.edu)
Structure-based redesign of lysostaphin yields potent 
antistaphylococcal enzymes that evade immune cell surveillance
Kristina Blazanovic1, Hongliang Zhao1,2, Yoonjoo Choi3, Wen Li1, Regina S Salvat1, Daniel C Osipovitch4, Jennifer Fields5,  
Leonard Moise6, Brent L Berwin5,7, Steven N Fiering5,7, Chris Bailey-Kellogg3 and Karl E Griswold1,7,8
ARTICle
2Deimmunized lysostaphin for S. aureus treatment
K Blazanovic et al.
Molecular Therapy — Methods & Clinical Development (2015) 15021 © 2015 The American Society of Gene & Cell Therapy
complex signaling cascade that drives T cell stimulation, B cell 
maturation, and ultimately production of class-switched IgG anti-
bodies that bind the offending biotherapeutic with high specific-
ity and affinity.17 Formation of antidrug antibodies may therefore 
be circumvented by engineering proteins so as to prevent molec-
ular recognition of constituent peptides, a process termed T cell 
epitope deletion.18,19
LST is a two domain protein, with an N-terminal glycylglycine 
zinc endopeptidase domain (LSTCAT) and a C-terminal SH3-like cell 
wall binding domain (LSTBD). This modular architecture, which is a 
common feature of many lytic enzymes,13,20 enables mix and match 
construction of chimeric cell wall hydrolases from natural catalytic 
and cell wall binding domains.21–26 Prompted by the modular nature 
of staphylolytic enzymes, we elected to pursue aggressive deimmu-
nization of the LSTCAT domain only, leaving the native LSTBD domain 
intact. We anticipated that a globally deimmunized catalytic 
domain would have broad utility as a fusion partner to any number 
of different bacterial targeting moieties, including both native and 
engineered cell wall binding domains.
In order to deimmunize LSTCAT, we applied the EpiSweep protein 
design algorithm27 to simultaneously optimize variants for two com-
peting objective functions: low immunogenic potential (assessed 
via predicted T cell epitope content) and retention of molecular fit-
ness (assessed via molecular mechanics energies). Variants whose 
predicted immunogenicities and molecular energies are not simul-
taneously dominated by any other single enzyme represent the 
Pareto optimal frontier of the protein design space.28 EpiSweep 
generates all such Pareto optimal variants along with successively 
sub-optimal designs,27 thereby enabling the selection of diverse 
candidates meriting experimental evaluation. A small panel of engi-
neered LSTCAT designs was selected, produced, and evaluated using 
both in vitro and in vivo assays of molecular function and immuno-
genicity. The results demonstrate efficient and effective production 
of deimmunized yet highly functional LST variants, some of which 
may ultimately prove useful in combatting MRSA and other danger-
ous S. aureus infections.
ReSUlTS
A predictive analysis identified putative T cell epitopes clustered 
throughout the LSTCAT sequence (Figure 1). To address this immu-
nogenicity risk, deimmunized LST variants were rapidly generated 
in a closed-loop engineering process that tightly coupled compu-
tational design and experimental analysis. Stage one narrowed the 
pool of prospective deimmunizing mutations to a functionally vali-
dated subset (Figure 2, left), and stage two integrated these individ-
ual mutations into globally deimmunized LSTCAT designs (Figure 2, 
right). In a subsequent third stage, the most promising lead candi-
dates were more rigorously characterized, including assessment of 
in vivo efficacy and immunogenicity in humanized mice. Detailed 
results from each stage of the process follow.
Stage 1: design and deimmunization priors
At the time of these studies, there was no available LSTCAT crystal or 
NMR structure, and a homology model was therefore constructed 
using the crystal structure of the homologous enzyme LytM29 
(Figure 2a,d inset). Overall, the LSTCAT and LytM sequences aligned 
closely, and there was a well-matched loop model for the one 
small region of LSTCAT that lacked a template segment in the LytM 
structure. As a result, the energy minimized model appeared to be 
of very high quality, attaining a QMEAN score of 0.63 (within the 
0.6–0.7 range typical of high resolution crystal structures).30
Figure 1 Epitope map of wild-type LSTCAT catalytic domain and positions of deimmunizing mutations. A map of predicted epitopes in wild type LSTCAT 
is shown as a bar plot, where amino acid positions are indicated on the x-axis and the number of MHC II alleles predicted to bind a given nonamer 
peptide are shown on the y-axis. Epitopes are indicated by bars at the first residue of the nonamer peptide. Epitopes cluster into five distinct regions 
shown as purple, blue, green, orange, and red bars, respectively. The positions of deimmunizing mutations are indicated with black triangles on the 
x-axis, and wild type residues are noted in red text. The mutational compositions of the seven characterized variants are shown below in black text, 
and the fraction of putative epitopes deleted by each mutation is indicated in parenthesis next to the mutant residue (i.e., “3/10” indicates deletion of 
3 out of 10 putative epitopes in that cluster).
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Computational methods, such as the EpiMatrix epitope predic-
tor31 used here, enable efficient analysis of epitopes in the wild-type 
sequence, as well as optimization of possible mutations for epitope 
deletion. The wild type LSTCAT domain, previously engineered to 
delete an N-linked glycosylation sequon,32 was predicted to con-
tain 21 nonamer peptides having 50 cumulative MHC II binding 
Figure 2 Two stage computationally-driven development of LSTCAT variants: Stage 1-left; stage 2-right. A structural map of putative LSTCAT epitope 
content bridges the Design Priors for both stages. Thick red tubes indicate dense, overlapping MHC II binding peptides, and thin white tubes indicate 
no predicted MHC II binding. (a) Priors for the initial design calculations identified allowed mutations based on their frequencies in a multiple sequence 
alignment of LSTCAT homologs, represented here as a logo plot. (b) Initial EpiSweep calculations generated an undominated Pareto optimal frontier, 
and near-optimal frontiers, at each mutational load. Mutational loads are: red = 8, blue = 7, purple = 6, green = 5, orange = 4, dark blue = 3, yellow = 2, 
black = wild type. X-axis is reduction in predicted epitope content and y-axis is computed molecular energy in arbitrary units, with wild type reference 
at 0. (c, top) Characterization of 15 individual point mutations that appeared frequently in designs from b. Expression level is shown in blue on left 
y-axis and specific lytic activity towards S. aureus in green on the right y-axis. (c, bottom) Predicted number of epitopes deleted by each point mutation. 
Validated substitutions selected for stage 2 protein design are highlighted in green boxes. (d) Priors for stage 2 design calculations were constrained 
to twelve specific mutations validated in c. Mutation S122D was included in all designs. (e) Final EpiSweep calculations generated a new set of Pareto 
optimal and near-optimal designs at mutational loads of 2–8 per enzyme, and fourteen candidates were selected for experimental analysis (indicated as 
filled diamonds). (f, top) Functional characterization of seven high expressing constructs. Apparent melting temperature is shown in purple on the left 
y-axis, and specific lytic activity in green on the right y-axis. (f, bottom) Measured MHC II binding for the seven engineered variants. Five corresponding 
constituent peptides from each LST design were evaluated for binding to eight different human MHC II proteins. Peptides were categorized as strong 
– red (IC50 < 0.1 µmol/l), moderate – orange (0.1 µmol/l ≤ IC50 < 1 µmol/l), weak – yellow (1 µmol/l ≤ IC50 < 10 µmol/l), or nonbinders (IC50 ≥ 10 µmol/l), 
and total counts of binders are shown for each variant. Variants F4a and F8a, highlighted in green boxes, were chosen for further analysis.
Design priors
Stage 1 Stage 2
Design priors
−30 −25 −20 −15 −10 −5
−15
−10
−5
0
50 300 Specific activity
(∆
m
fi ×
 µg
−1
 ×
 s
−1)
Specific activity
(∆
m
fi ×
 µg
−1
 ×
 s
−1)
200
150
100
50
0
200
100
0
Expression level
Characterization Characterization
Specific activity
40
30
Ex
pr
es
sio
n 
le
ve
l (m
g/l
)
20
10
0
60
50
40
30
Ex
pr
es
sio
n 
le
ve
l (m
g/l
)
20
10
0
5
En
er
gy
10
EpiSweep design EpiSweep design
N12G, N13H, I41E,
K46H, L83M, Y93H,
K95E, I99Q, R118T,
N121G, S122D, S124G
0
∆ Epitope score
−30 −25 −20 −15 −10 −5
−15
−10
−5
0
En
er
gy
0
Specific activity
Strong
18
10
8
6
4
2
0
15
12
M
ea
su
re
d 
ep
ito
pe
 c
ou
nt
Pr
ed
ict
ed
 e
pi
to
pe
 d
el
et
io
n
9
6
3
0
Moderate Weak
Tm
∆ Epitope score
Wi
ld 
typ
e F2 F3 F4
a
F4
b
F5
b
F6
b
F8
a
Wi
ld 
typ
e F2 F3 F4
a
F4
b
F5
b
F6
b
F8
a
S1
24
Y
S1
24
G
S1
22
G
S1
22
D
N1
21
G
R1
18
T
I99
Q
K9
5E
Y9
3H
L8
3M
K4
6HI41
E
F3
8G
N1
3H
N1
2G
Wi
ld 
typ
e
S1
24
Y
S1
24
G
S1
22
G
S1
22
D
N1
21
G
R1
18
T
I99
Q
K9
5E
Y9
3H
L8
3M
K4
6HI41
E
F3
8G
N1
3H
N1
2G
Wi
ld 
typ
e
a d
b e
c f
4Deimmunized lysostaphin for S. aureus treatment
K Blazanovic et al.
Molecular Therapy — Methods & Clinical Development (2015) 15021 © 2015 The American Society of Gene & Cell Therapy
interactions with the eight most common MHC II alleles (Figure 1). 
The majority of putative epitopes clustered into five distinct regions 
(named C1WT to C5WT), two of which exhibited dense, overlapping, 
and highly promiscuous MHC II binding (Supplementary Figure S1, 
clusters C2WT and C5WT). These epitope hotspots were distributed 
throughout the LSTCAT molecular structure (Figure 2a,d inset).
In stage 1, prospective deimmunizing mutations were limited to 
a set of 36 amino acid substitutions at 20 different residue positions. 
The allowed mutations were identified based on frequency in a set 
of diverse LSTCAT homologs (Figure 2a), constraining that subset to 
avoid known detrimental mutations, avoid active site residues, and 
require deletion of at least one putative epitope.
Initial computational designs
Based on the deimmunization priors, EpiSweep generated a total 
of 1,663 designs having two to eight mutations each. The protein 
plans mapped a Pareto optimal frontier in the two-dimensional 
energy score versus epitope score design space, and the design 
set also included 19 near-optimal frontiers at each mutational load 
(Figure  2b). As seen in the graphic, increased aggressiveness in 
deleting epitopes (lower epitope score) requires an increased ener-
getic penalty higher energy score), though many of the designs 
have better predicted energy than wild type, and no penalty is par-
ticularly severe. As is typically observed, higher mutational loads 
(left most sets of frontiers) leverage combinations of mutations 
to achieve a desired reduction in epitope content, and relative to 
aggressive single mutations, these combinations incur a smaller 
energetic penalty. Conversely, to achieve a given epitope score at 
lower mutational loads, each mutation must delete a larger relative 
number of epitopes, and these more aggressive substitutions tend 
to have a greater energetic cost. Compare, for example, the ener-
gies of designs having identical epitope scores but four mutations 
(in orange) versus eight mutations (in red) (Figure 2b).
Functional analysis of point mutants
While the ultimate goal was production of integrated  multi-mutation 
variants, we first sought to quickly identify and eliminate detrimental 
mutations that individually undermined expression or activity. The 
15 mutations appearing most frequently among the initial designs 
were individually introduced into the aglycosylated  wild-type 
LST backbone.32 Mutant genes were cloned into Pichia pastoris, 
expressed on a small scale, and LST activities and expression levels 
were determined by analysis of crude culture supernatants. Based 
on densitometry of polyacrylamide gels (Supplementary Figure S2), 
10 variants had expression yields greater than or equal to 90% 
wild type, with only 2 variants exhibiting less than 70% wild type 
expression (Figure 2c, variants R118T = 47% and S124Y = 35%). Lytic 
activities towards S. aureus strain SA113 were quantified using a 
fluorometric kinetic assay, and rates were normalized to estimated 
expression levels. Thirteen of 15 variants had estimated specific 
activities equal to or greater than wild type (Figure  2c). The two 
exceptions, variants F38G and S124Y, experienced 30 and 84% rate 
reductions, respectively.
Stage 2: deimmunization priors
According to the stage 1 functional analysis (Figure 2c), F38G and 
S124Y were deemed detrimental and excluded from future designs. 
Mutation S122G, although fully functional, was also excluded, as it 
targeted the same epitope cluster as S122D but did so less effec-
tively (deleting only 3 putative epitopes as opposed to a net of 10, 
respectively, Figure 2c and Supplementary Figure S1). Given the fact 
that S122D was a particularly efficient epitope silencer (Figure  2c 
and Supplementary Figure S1), it was specifically incorporated into 
all stage 2 plans. Thus stage 2 design considered 11 prospective 
mutations (in addition to S122D): N12G, N13H, I41E, K46H, L83M, 
Y93H, K95E, I99Q, R118T, N121G, and S124G (Figure 2d).
Lead computational designs
Based on this more restricted set of prospective deimmunizing 
mutations, EpiSweep was again implemented to generate Pareto 
optimal frontiers and near-optimal frontiers. It optimized a total of 
1,400 variants with mutational loads from two to eight (Figure 2e). 
With the reduced pool of candidate mutations, there was less dis-
tinction between the curves for different mutational loads, but the 
same trade-off between deimmunizing aggressiveness and ener-
getic penalty was observed.
Prior to candidate selection, each of the designs was subjected 
to global energy minimization, allowing both side chains and 
backbone atoms to relax. Fourteen low energy designs at muta-
tional loads of two to eight were selected for experimental analysis 
(Supplementary Table S1). Among selected designs, predicted epi-
tope scores ranged from 36 to 24, corresponding to a 28–52% reduc-
tion in epitope content relative to wild type (epitope score = 50).
Functional analysis of globally deimmunized variants
The 14 chosen designs were cloned, expressed, purified, and sub-
jected to preliminary analysis (Supplementary Table S1). Seven of 
the 14 variants expressed at reasonable levels (≥30% wild type), and 
apparent melting temperatures for these enzymes ranged from 89 
to 99% that of wild-type LST (Figure 2f ). The activity of the seven 
designs was assessed using a fluorometric kinetic assay of bacterial 
lysis, and all variants maintained specific lytic rates greater than 50% 
that of wild type (Figure 2f). Overall, the engineered designs exhib-
ited good thermostability and high levels of antibacterial activity, 
despite having as many as eight mutations in the catalytic domain. 
Interestingly, the seven designs that initially failed to express all 
encoded the R118T mutation, which by itself had resulted in a 50% 
reduction in expression levels (Figure  2c). Reversion of this single 
mutation restored expression in all seven associated designs, and 
the seven reverted variants were all found to have good activity 
and stability (Supplementary Table S1). Thus, 80% of the prospec-
tive deimmunizing mutations selected by EpiSweep in stage 1 pro-
duced stable and functional enzymes when combined as integrated 
designs, although preanalysis as individual point mutations was 
a key step in rapidly eliminating deleterious substitutions (F38G, 
S124Y, and in hindsight, R118T).
Immunoreactivity by peptide-MHC II binding assays
To deimmunize a biotherapeutic agent, the EpiSweep algorithm seeks 
to disrupt class II MHC binding of peptide fragments derived from the 
protein. As a measure of success, competition binding assays33 were 
performed with recombinant human MHC II, known peptide anti-
gens, and LSTCAT peptide fragments. Peptides representing wild-type 
LSTCAT epitope clusters (Supplementary Figure S1) were synthesized, 
as were cognate peptides derived from each of the seven successfully 
expressed designs from Supplementary Table S1. Peptide affinities for 
MHC II proteins were categorized as either strong (IC50 < 0.1 μmol/l), 
moderate (0.1 μmol/l ≤  IC50 < 1 μmol/l), weak (1 μmol/l ≤  IC50 < 10 
μmol/l), or nonbinders (IC50  ≥  10 μmol/l). High-affinity interaction 
between peptide antigens and class II MHC is a key determinant of 
5Deimmunized lysostaphin for S. aureus treatment
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subsequent T cell immunogenicity,34–36 and all five wild-type LST pep-
tides exhibited submicromolar IC50’s for at least one human MHC II 
protein (Supplementary Table S2). Peptides C3WT, C4WT, and C5WT 
proved to be promiscuous tight binders, each exhibiting high-affinity 
interactions with three to four MHC II alleles.
The peptide-MHC II binding analysis included a total 26 peptides 
and eight MHC II alleles yielding 208 separate affinity determina-
tions. Of the 168 pairs of wild-type and cognate deimmunized 
affinities, there were 63 instances in which the deimmunizing 
mutations reduced affinity by greater than 10-fold and/or ablated 
binding entirely (i.e., IC50 > 250 μmol/l, Supplementary Figure S3). 
There were another 13 cases in which the mutation reduced bind-
ing by 5- to 10-fold. In contrast, there were only 14 examples of 
>10-fold enhanced binding by a variant peptide, and notably 
seven of these were instances in which the corresponding wild-
type peptide was already a high-affinity binder (Supplementary 
Table S2, C2WT variants and C5WT variants with allele 0101). To 
correlate the experimentally measured MHC II affinities with the 
algorithm’s binary prediction of peptide binding/nonbinding, 
an experimental binding threshold was set at IC50  ≤  10 μmol/l, 
i.e., counting all strong, moderate, and weak binders as defined 
above. Given this experimental threshold and an EpiMatrix pre-
diction threshold of 5%, the protein design process yielded a 69% 
positive prediction rate across all eight alleles (Supplementary 
Table S2). Overall, we observed a 10% false-positive rate and a 
21% false-negative rate, similar to those we have reported previ-
ously.37–39 At the level of individual peptides, EpiSweep efficiently 
identified both high affinity  MHC-binders and disruptive muta-
tions, realizing a 37.5% success rate in ablating binding and/or 
reducing affinity by more than 10-fold.
For each of the stage 2 variants that expressed as originally 
designed, a categorical immunoreactivity score was obtained by 
summing the number of strong, moderate, and weak MHC bind-
ers among each protein’s component peptides (5 peptides • 8 MHC 
alleles = 40 possible interactions per protein). Wild type LSTCAT pos-
sessed 11 strong, 4 moderate, and 4 weak binding interactions. As 
predicted by the Episcore design parameter (Supplementary Table 
S1), immunoreactivity generally decreased across the panel of 
variants from F2 to F8 (Figure  2f ). Variant F8a in particular exhib-
ited dramatically reduced immunoreactivity, disrupting 10 of 11 
strong binders from wild-type LST. At a more moderate mutational 
load, variant F4a eliminated three strong binders and manifested 
an overall reduction of five binding interactions. Given their strong 
performance during preliminary in vitro characterization, these two 
deimmunized candidates were selected for more detailed func-
tional and immunogenicity analysis.
Stage 3: stability and antibacterial activity of lead candidates
Variants F4a and F8a were expressed, purified, and characterized in 
biological duplicate. In addition to our own recombinant wild type 
LST,32 LST was obtained from a commercial supplier and analyzed 
in parallel. The apparent melting temperatures of both F4a and F8a 
were consistent with values obtained during preliminary testing, 
but their specific rates of bacterial lysis were found to be some-
what higher upon more rigorous analysis (Table  1). Importantly, 
the deimmunized variants were equivalent to or better than com-
mercially sourced LST in both assays. The enzymes’ antibacterial 
activities were further quantified by assessing minimal inhibitory 
concentration (MIC) towards four strains of S. aureus. The F4a MIC 
for strain SA113 was equivalent to that of wild type and commercial 
LST, and it was within a single 2-fold serial dilution for three clini-
cal isolates, including MRSA strain 3425-3. Variant F8a also retained 
good bactericidal/bacteriostatic activity, preventing outgrowth of 
all four strains at 200 ng/ml (~7 nmol/l) or less. Given the fact that 
the LSTCAT variants encoded four or eight mutations, respectively, 
their high levels of anti-staphylococcal activity were striking.
In vivo efficacy and immunogenicity of lead candidates
To assess antibacterial activities in a more clinically relevant fashion, 
we employed a murine lung infection model using an S. aureus clini-
cal isolate. Mice were infected with live bacteria via oropharyngeal 
aspiration, and one hour later they were treated via the same route 
with a solution containing 2.5 μg of wild type LST, variant F4a, or 
variant F8a. Twenty-four hours post infection, mice were sacrificed, 
lungs were harvested, and viable bacterial counts were determined 
by plating serial dilutions of lung homogenate. All three enzymes 
yielded a statistically significant 10-fold reduction in bacterial bur-
den relative to a saline buffer control (one-way analysis of variance 
P = 0.007, Tukey post hoc test), but there was no significant differ-
ence between the three treatments (Figure  3a). Thus, the deim-
munized candidates retained wild type efficacy in the infected and 
inflamed lung environment.
In vivo immunogenicity was evaluated using NOD/SCID/γc-/- mice 
that had been surgically humanized with human immune cells, liver 
tissue, and thymus tissue (BLT mice). Following transplantation of 
human tissues at 6 weeks of age, BLT mice were allowed to mature 
and develop circulating repertoires of human B and T cells. At 14 
weeks posttransplantation, mice were divided into three groups of 
four each and immunized subcutaneously with 100 ug of wild-type 
LST, F4a, or F8a in adjuvant. Thirteen days post immunization, mice 
were sacrificed, splenocytes were harvested and pooled for each 
group, and the pooled cells were subjected to ex vivo restimulation 
Table 1 Detailed performance analysis of deimmunized LST designsa
Design  
ID
%WT  
lytic rate
Tm  
(°C)
MIC (µg/ml)
Strain 1  
SA113
Strain 2  
6445
Strain 3  
3425-1
Strain 4  
3425-3
Wild type 100 ± 30 59.0 ± 0.4 0.02 ± 0.00 0.03 ± 0.01 0.04 ± 0.02 0.03 ± 0.02
Commercial 60 ± 20 47.3 ± 0.4 0.03 ± 0.00 0.03 ± 0.00 0.04 ± 0.01 0.03 ± 0.00
F4a 70 ± 30 55.8 ± 0.2 0.02 ± 0.01 0.06 ± 0.04 0.11 ± 0.09 0.05 ± 0.03
F8a 60 ± 20 52.8 ± 0.3 0.04 ± 0.01 0.13 ± 0.07 0.2 ± 0.1 0.2 ± 0.1
LST, Staphylococcus simulans lysostaphin; MIC, minimal inhibitory concentration.
aErrors are standard deviation from a minimum of biological duplicates measured in triplicate.
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with their cognate proteins. Cell proliferation was measured by triti-
ated thymidine uptake at 72 hours, and the stimulation index (pro-
tein versus DMSO proliferative response) was 1.6-fold for wild-type 
LST (Figure 3b). While this stimulation index is lower than the two-
fold to threefold cutoff sometimes used in experiments with periph-
eral blood mononuclear cells taken directly from human subjects, 
it bears noting that T cells from humanized mice are widely known 
to exhibit impaired function. In particular, humanized mouse sple-
nocytes yield poor ex vivo proliferative responses (e.g., twofold 
stimulation index) even to potent stimulatory agents such as phy-
tohaemagglutinin, ionomycin-PMA, keyhole limpet hemocyanin, 
and anti-CD3/anti-CD28 antibody cocktails.40,41 Thus, the significant 
(P = 0.0005, two-way analysis of variance) 1.6-fold stimulation index 
observed here with splenocytes from mice immunized with wild 
type LST is a reasonable indicator of an antigen specific immune 
response, particularly given the fact that the mice of the current 
study received only a single immunization. Relative to the wild type 
LST immunized group, pooled splenocytes from F4a and F8a immu-
nized mice exhibited significantly reduced proliferation (Figure 3b). 
After background subtraction, F4a pooled cells showed a 50% 
reduced response and F8a pooled cells a 65% reduced response.
In addition to inherent immunogenicity in the context of a naive 
immune system, we also considered the extent to which a deim-
munized protein might evade an established memory response 
directed against the wild type LST sequence. Due to the long time-
frame of such a study and the short lifespan of BLT mice, we elected 
to assess the memory response in transgenic DR4 mice. This homo-
zygous strain bears a chimeric class II MHC derived from murine sig-
naling domains and the peptide binding domains of human HLA 
DRA and DRB1*0401.42 This stable transgenic model has a normal, 
healthy lifespan enabling extended studies, yet it manifests human 
antigen presentation specificity. To establish an anti-LST immune 
response, 10 DR4 mice were immunized and repeatedly boosted 
with sub-cutaneous injections of wild type LST. Nineteen weeks 
after the final boost, mice were divided into two groups of five 
each such that each group exhibited similar average antibody titers 
(Supplementary Figure S4). Mice were then rechallenged with either 
100 μg wild-type LST or 100 μg variant F4a. Thirteen days later, sple-
nocytes were harvested, pooled for each group, and subjected to 
ex vivo restimulation with the cognate protein from the final rechal-
lenge. Similar to the results in the BLT mice, ex vivo restimulation 
of DR4 splenocytes with wild type LST yielded a  1.8-fold stimula-
tion index (Figure 3c). It bears noting that similarly small stimulation 
indices in DR2, DR3, and DQ8 transgenic mice have been shown to 
correlate with antigen specific immune responses.43 Thus, the signif-
icant (P = 0.0002, two-way analysis of variance)  1.8-fold stimulation 
index seen here was a reasonable indicator of an anti-drug immune 
response. In contrast to mice rechallenged with wild-type LST, 
pooled splenocytes from the F4a rechallenge group exhibited no 
detectable proliferation above background levels (Figure 3c). Thus, 
immune cells primed to recognize wild type LST exhibited reduced 
activity upon rechallenge with F4a, suggesting that the deimmu-
nized variant effectively evaded the memory response directed 
against the wild type enzyme.
DISCUSSION
LST is a potent bacteriolytic enzyme and a promising candidate for 
combating S. aureus infections. However, its inherent immunoge-
nicity poses a barrier to clinical translation. Prior studies sought to 
shield LST from the immune system via conjugation with polyethyl-
ene glycol (PEGylation).44 While PEGylation reduced LST immunore-
activity and elongated serum half-life, it was ultimately found that 
covalent coupling to PEG inactivated the enzyme; residual activity 
in PEGylated samples was due to LST that had been noncovalently 
and reversibly associated with the polymer.15 Here, we have taken 
an alternative approach to mitigating LST immunogenicity, employ-
ing a structure-based deimmunization algorithm to design variants 
having reduced T cell epitope content yet high levels of antibacte-
rial activity. Importantly, neither an LST x-ray crystal structure nor an 
NMR structure was available, and we therefore built a model based 
on the structure of the homologous enzyme LytM.29 Leveraging 
this molecular model and a Pareto optimal deimmunization 
Figure 3 In vivo efficacy and immunogenicity analysis. (a) Bacterial burden in the lungs of C57Bl/6 mice following infection with S. aureus and treatment 
with wild type LST (red), variant F4a (dark blue), variant F8a (light blue), or a PBS control (black). Shown are mean values and standard deviations (n = 6 
per group). (b) BLT mice (all humanized from a single donor) were immunized subcutaneously with either wild type LST, variant F4a, or variant F8a, 
and splenocytes were harvested and restimulated ex vivo with the same protein or DMSO. Proliferation was measured as uptake of tritiated thymidine. 
Shown are mean values and standard deviations (n = 4 per group, pooled and measured in triplicate). (c) Transgenic DR4 mice were immunized with 
multiple subcutaneous injections of wild-type LST. Following the final boost, mice were allowed to recover for 20 weeks, divided into two groups, and 
rechallenged with either wild type LST or variant F4a. Splenocytes were harvested and restimulated ex vivo with the rechallenge protein or DMSO, and 
proliferation was measured as uptake of tritiated thymidine. Shown are mean values and standard deviations (n = 5 per group, pooled and measured 
in triplicate). Statistical significance was assessed by one-way analysis of variance (panel a) or two-way analysis of variance (panels b and c). *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001.
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methodology, we were able to employ high mutational loads to 
simultaneously redesign as many as five broadly distributed epi-
tope clusters in the LST catalytic domain.
The most recent advances in lytic enzyme biotherapies include 
construction of synthetic antibacterial enzymes based on chime-
ragenesis of modular lysin domains.13,20–26 We anticipated that a 
deimmunized LST catalytic domain would prove useful as a fusion 
partner to a wide variety of cell wall targeting entities, and we there-
fore focused our deimmunization efforts on LSTCAT, leaving the LSTBD 
cell wall binding domain in its native form. Interestingly, we found 
that deimmunization of the catalytic domain was sufficient to sup-
press the cellular immune response against full length fusion pro-
teins that bore the native LSTBD sequence. We therefore speculate 
that immunodominant LST epitopes are localized predominantly 
to the catalytic domain, although a rigorous test of this hypothesis 
awaits more detailed experimental analyses of the phenotype and 
function of cells that proliferate in response to various constructs. 
Regardless, mutations targeted to three of five (in the case of F4a) or 
five of five (in the case of F8a) putative epitope clusters in the cata-
lytic domain produced marked reductions in global immunoge-
nicity, as measured by ex vivo proliferative response of humanized 
murine splenocytes following in vivo immunization with full length 
fusion proteins. At the same time, both variants exhibited wild-type 
efficacy in a murine lung infection model, a highly relevant system 
given the prevalence of S. aureus in both hospital and community 
acquired pneumonias.2 Taken as a whole, these results show that 
the EpiSweep algorithm efficiently identified mutations and com-
binations of mutations that suppressed LST immunogenic poten-
tial while maintaining high level therapeutic activity. Should the 
enzymes’ ability to evade immune cell surveillance ultimately trans-
late into suppressed antidrug antibody responses, one key impedi-
ment to LST clinical development will have been addressed. More 
generally, we expect that a similar strategy could be employed with 
other bacteriolytic drug candidates, many of which are known to 
elicit an undesirable immune response in preclinical models.13
Therapeutic enzymes’ mechanisms of action are fundamentally 
grounded in reaction catalysis, and the inherent complexity of their 
sequence-structure-function relationships may render them partic-
ularly sensitive to disruption by molecular manipulations. As a result, 
there are currently only six enzymes that have been successfully 
engineered by T cell epitope deletion.37,38,45–51 The work described 
here represents an important contribution to this space. First, the 
threat of drug-resistant bacterial infections is driving growing inter-
est in antibacterial enzymes, and this report is the first and currently 
only example of a bacteriolytic biocatalyst deimmunized via T cell 
epitope deletion. Second, and more generally, this work serves as 
a preliminary validation of an efficient and effective computation-
ally driven deimmunization process that is broadly applicable and 
might enable deimmunization of other challenging biotherapeutic 
targets. To be sure, humanized mouse models have limitations, and 
the success of protein deimmunization must ultimately be mea-
sured in the clinic. Nevertheless, the results of EpiSweep deimmuni-
zation efforts with both LST and P99 beta-lactamase52 suggest that 
the methodology holds great promise as a general tool for acceler-
ating biotherapeutic deimmunization and development.
MATeRIAlS AND MeTHODS
Reagents and media
Primers were ordered with standard desalting from IDT Technologies 
(Coralville, IA). Commercial lysostaphin, SYPRO Orange 5000x Protein 
Stain, and crystal violet dye were purchased from Sigma (St Louis, MO). 
All enzymes were obtained from New England BioLabs (Ipswich, MA), 
and all reagents from VWR Scientific (Philadelphia, PA), unless otherwise 
noted. Peptides derived from the LST catalytic domain were ordered from 
GenScript (Piscataway, NJ), and were greater than 85% pure. MHC-II DR 
molecules were purchased from Benaroya Research Institute (Seattle, WA), 
 anti-MHC-II-DR antibody from Biolegend (San Diego, CA), and DELFIA 
Eu-labeled Streptavidin was from PerkinElmer (Boston, MA).
Murine model studies
The protocols for animal infection, immunization, and treatment were 
approved by the Institutional Animal Care and Use Committee of Dartmouth 
College (Hanover, NH), in accordance with the Association for the Assessment 
and Accreditation of Laboratory Animal Care Guidelines. All efforts were 
made to minimize animal suffering. All in vivo studies used recombinant wild 
type LST that had been produced and purified in house, and differed from 
variants F4a and F8a by only the deimmunizing mutations.
Plasmids and strains
P. pastoris strain GS115 and expression vector pPIC9 were from Invitrogen 
(Grand Island, NY). S. aureus strains SA113 and S. aureus subsp. aureus (ATCC 
25923) were obtained from the American Type Culture Collection (Manassas, 
VA). Other clinical isolates of S. aureus (methicillin sensitive strains 6445 and 
3425-1, and MRSA strain 3425-3) were the kind gift of Dr Ambrose Cheung 
(Dartmouth, Hanover, NH).
Homology modeling
An LSTCAT structural model was constructed using three LytM structures as 
templates (1QWY:A, 2B0P:A, and 2B44:A). Two hundred and fifty models 
were constructed using MODELLER (Ver. 9.11; ref. 53) and the best model 
was selected according to the DOPE potential.54 The templateless region at 
24 PLGINGG was separately modeled using FREAD,55 which identified 180 
PRGEEGG in 1GMN:A as the best match. The modeled loop structure was 
grafted on, and the entire model was minimized using TINKER56 against 
AMBER99sb57 with GB/SA.58 The aglycosylated wild type (125 NPT) was mod-
eled by applying in silico mutations to the original model using Scwrl4,59 fol-
lowed by energy re-minimization.
Epitope prediction
Epitopes were predicted by the EpiMatrix pocket profile method.31 
Considered epitopes were limited to those in the top 5% of predicted bind-
ers against MHC II alleles DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301, 
and 1501, which are broadly representative of global populations.36
Stage 1 allowed mutations
A total of 10,000 homologs to LSTCAT were collected by running PSI-BLAST60 
(3 iterations, e-value <0.001). These sequences were filtered to remove those 
with >50% gaps or <35% sequence identity to the wild-type. A diverse set 
of 218 representative sequences was subselected so as to have at most 90% 
sequence identity to each other. Allowed mutations were those predicted 
to delete at least one putative epitope while appearing as frequently as 
expected in terms of a background probability distribution.61 Additional fil-
ters excluded mutations to/from Pro and Cys, mutations involving active site 
residues (32H, 36D, 82H, 113H, and 115H), and mutations previously found 
to be detrimental (T43D, S50D, N121D, and L135S).
Computational deimmunization
EpiSweep integrates epitope prediction and molecular mechanics energy 
evaluation in order to simultaneously reduce epitope content while main-
taining stability and function. It employs an optimization algorithm that 
identifies all designs making optimal trade-offs between these criteria 
(the Pareto frontier) at a specified mutational load; it can be iterated to 
identify successively near-optimal frontiers. Here, EpiSweep was applied 
as previously described,27 though using the EpiMatrix epitope predictor as 
discussed above. Mutations were restricted to those specified in the deim-
munization prior, though all side-chains were allowed to change rotameric 
conformation in the search for low energy enzyme designs predicted to 
maintain the parental enzyme’s antibacterial activity. Molecular mechanics 
energies (a proxy for stability and thereby maintenance of function) were 
computed according to AMBER62 as implemented under the open source 
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protein design software OSPREY.63 For each stage and each mutational load 
from 2 to 8, the Pareto frontier designs were supplemented with designs 
comprising 19 successive near-optimal frontiers.
Stage 2 lead variants were selected for a combination of factors includ-
ing mutational load, minimized energy, and epitope score. All designs were 
energy minimized following the same protocol described in Homology 
Modeling section (all-atom minimization under AMBER99sb with GB/SA via 
the Tinker package). Designs were chosen across the epitope score range 
from 24 to 36 at intervals of 2 (compared to wild-type at 50). A total of 14 
designs were selected for experimental analysis (Supplementary Table S1).
Cloning of LST single point mutants
Genes encoding LST single point mutants were synthesized by splice over-
lap extension PCR with synthetic oligonucleotides (Supplementary Table S3) 
and an optimized synthetic gene encoding the S126P aglycosylated protein 
backbone.32 All PCR reactions were performed using Phusion®  High-Fidelity 
DNA polymerase. The lysostaphin gene harboring the desired mutations 
was digested with EcoRI and XhoI, and ligated into the pPIC9 plasmid using 
T4 DNA ligase. The end product of ligation was the lysostaphin gene fused 
to the alpha mating factor secretion signal from Saccharomyces cerevisiae. 
The plasmid was transformed into E. coli DH5α electrocompetent cells 
[F- ɸ80lacZΔM15Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 ( )r mK K− +  phoA 
supE44 λ- thi-1 gyrA96 relA1]. Clones were evaluated for the presence of lyso-
staphin gene using Syn_F and Syn_R primers and sent for DNA sequencing 
to confirm the presence of mutations.
Cloning of LST integrated designs
Lysostaphin variants were synthesized with standard desalting as 432 bp 
long gBlocks® gene fragments by IDT Technologies (Coralville, IA). To prepare 
the pPIC9 plasmid for insertion of synthesized genes, a silent mutation was 
introduced into the lysostaphin linker (residues 135–136) to accommodate a 
cutting site for the restriction enzyme AflII. To introduce the necessary muta-
tions, splice overlap extension PCR was used with primers AflII_F and AflII_R 
(Supplementary Table S3). The synthetic genes were digested with XhoI and 
AflII restriction enzymes, and ligated in similarly digested pPIC9 plasmid 
using T4 DNA ligase. The resulting plasmid was transformed into E. coli DH5α 
electrocompetent cells and the resulting clones were sequenced to confirm 
the presence of mutations.
LST expression and purification
Following sequence confirmation, purified plasmids were digested with 
SacI High-Fidelity restriction enzyme prior to electroporation into P. pastoris 
strain GS115. The resulting transformants were grown on MD plates (1.34% 
yeast nitrogen base (YNB), 0.000004% biotin, 2% dextrose, and 1% agar). For 
expression studies, P. pastoris clones were grown in 100 ml BMGY medium 
(1% yeast extract, 2% peptone, 1.34% YNB, 0.000004% biotin, 1% glycerol, 
100 mmol/l phosphate buffer, pH 6) at 30 °C in 500 ml shake flasks covered 
with four layers of cheese cloth for enhanced oxygen flow to the yeast. After 
24 hours, cells were centrifuged at 3,000 rpm in a table top centrifuge for 10 
minutes. The cells were then resuspended in 100 ml of induction medium 
(BMMY: 1% yeast extract, 2% peptone, 1.34% YNB, 0.000004% biotin, 0.5% 
methanol, 100 mmol/l phosphate buffer, pH 6) and allowed to grow for the 
next 48 hours at 30 °C. At 12-hour intervals, a 1/100 v/v aliquot of 100% 
methanol was added to the flasks. After 48 hours of induction, shake flask 
culture was centrifuged in a table top centrifuge at 3,000 rpm for 15 minutes. 
The resulting supernatant was sterile filtered to remove any yeast cells and 
diluted 1:5 with 10 mmol/l KH2PO4 buffer at pH 7.5. Diluted supernatant was 
poured over a gravity column packed with 500 µl SP-Sepharose Fast Flow 
resin (GE Healthcare; Cleveland, OH). The column was washed with 5 ml of 50 
mmol/l NaCl in 10 mmol/l KH2PO4 at pH 7.5. Protein was eluted with 500 µl 
aliquots of 200 mmol/l NaCl in 10 mmol/l KH2PO4, pH 7.5. The purity of lyso-
staphin was determined using SDS–PAGE. The protein concentration was 
quantified using ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE).
Lytic assay
S. aureus cells were grown either to mid-log or to saturation in tryptic soy 
broth (TSB) at 37 °C with shaking. The cells were harvested by centrifuga-
tion and washed once in phosphate buffered saline (PBS: 2.7 mmol/l KCl, 1.5 
mmol/l KH2PO4, 8.9 mmol/l Na2HPO4, 136.9 mmol/l NaCl, pH 7.4). The assay 
was performed in 96-well, black, clear bottom plates from Greiner Bio-One 
(Monroe, NC). The final reaction volume (250 µl in PBS) consisted of 10 µl of 
P. pastoris culture supernatant (or 200 ng of purified protein), S. aureus cells 
at OD600 = 1.5, and 5 µmol/l SYTOX Green (Thermo Fisher Scientific; Waltham, 
MA). Data was collected using SpectraMax Gemini Fluorescence Microplate 
Reader (Molecular Devices, Sunnyvale, CA) using an excitation/emission 
of 504/523 nm, and rates were determined from the slope of the steepest 
linear portion of the trace. For the assays performed using P. pastoris cul-
ture supernatant, the amount of protein used in each assay was quantified 
from SDS–PAGE using Quantity Tools from Image Lab 5.1 software (Bio-Rad 
Laboratories, Hercules, CA) (note that in some cases values were extrapo-
lated from the explicitly measured standard curve).
MIC assay
The MICs of wild type LST and deimmunized variants were determined by 
adding twofold serial dilutions of enzymes into wells of a polypropylene 
96-well plate (Costar 3879) containing ~40,000 S. aureus (strains SA113, 6445, 
3425-1, or 3425-3) cells in Muller Hinton II broth (BD) supplemented with 2% 
NaCl and 0.1% bovine serum albumin, yielding a total volume of 100 µl. Plates 
were grown overnight at 37 °C with shaking at 900 rpm on an Orbit P4 orbital 
shaker (Labnet, Edison, NJ). The inhibitory activity of purified lysostaphin was 
determined by the concentration of enzyme that prevented visible bacterial 
outgrowth. The assay was performed in triplicate for each enzyme.
Thermostability assay
The relative thermostability of the LST variants was determined by differ-
ential scanning fluorimetry, as previously described.64 Briefly, proteins and 
SYPRO Orange were diluted in PBS (final concentrations of 100 µg/ml and 5× 
in 20 µl reaction volume, respectively), and fluorescence was quantified at 
1-degree increments from 25 to 94 °C using an Applied Biosystems ABI 7500 
fast real-time PCR system. The reactions were performed using PCR Plates 
for Fast Thermocyclers (VWR, Radnor, PA). Fluorescence was quantified using 
the preset TAMRA parameters. Melting temperatures were determined by 
data analysis with the “DSF Analysis v3.0.xlsx” Excel sheet (ftp://ftp.sgc.
ox.ac.uk/pub/biophysics/) and GraphPad Prism v.6.02 software (GraphPad 
Software, La Jolla, CA).
MHC binding assays
MHC II competition binding assays were performed using a 384-well 
 high-throughput assay as previously described.34 Binding assays were per-
formed for the eight alleles: DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301, 
and 1501. Briefly, 100 nmol/l biotinylated control peptides consisting of 
known peptide antigens for each MHC II allele were incubated in polypro-
pylene 384-well plates with 50 nmol/l purified recombinant MHC II protein 
and serial dilutions of LST or variant peptide fragments (100 μmol/l to 10 
nmol/l). Peptide-MHC II complexes were captured from equilibrated solu-
tions using the conformation specific anti-HLA-DR antibody L243 coated on 
high binding ELISA plates. Bound control peptide was quantified using the 
DELFIA streptavidin-Europium conjugate and time resolved fluorescence 
(SpectraMax Gemini Fluorescence Microplate Reader).
Murine lung infection model
Overnight LB cultures of S. aureus strain ATCC 25923 were pelleted, washed 
twice with PBS, and resuspended to give 108–109 colony-forming units (CFU) 
in 40 μl of PBS. The actual inoculum was determined by serial dilution of the 
input bacterial suspension on LB agar (Difco), followed by incubation at 37 
°C for 24 hours. Adult female C57BL/6J mice (age, 8 to 12 weeks; Jackson 
Laboratories, Detroit, MI) were anesthetized briefly with isoflurane and inoc-
ulated with 40 μl of bacterial suspension via oropharyngeal aspiration. At 1 
hour postinfection, a second 40 μl PBS inoculation containing either 2.5 μg 
wild-type LST, 2.5 μg variant F4a, 2.5 μg variant F8a, or a blank control. At 
24 hours postinfection, mice were sacrificed and lungs were excised, placed 
into 1 ml of cold PBS, and homogenized. Viable bacterial counts in the lung 
homogenate were determined by plating serial dilutions onto LB agar, fol-
lowed by incubation at 37 °C for 24 hours.
BLT murine immunogenicity studies
BLT mice were constructed by surgical transplantation of human bone 
marrow, liver, and thymus tissues into NOD/SCID/γc-/- mice (Dartmouth 
9Deimmunized lysostaphin for S. aureus treatment
K Blazanovic et al.
Molecular Therapy — Methods & Clinical Development (2015) 15021© 2015 The American Society of Gene & Cell Therapy
Transgenics & Genetic Constructs Shared Resource) as described in 
detail elsewhere.65 All animals were humanized using tissue from a single 
DRB1*0101/DRB1*0701 heterozygous donor. Mice used experimentally had 
human lymphocytes as a minimum of 25% of their total peripheral blood 
leukocytes. Fourteen weeks post engraftment, 12 female BLT mice were 
divided into 3 groups of 4 each and immunized with a single 50 μl subcuta-
neous injection of 100 μg wild type LST, 100 μg variant F4a, or 100 μg variant 
F8a in complete Freund’s adjuvant (CFA). Two weeks following the immuni-
zation, mice were sacrificed and splenocytes were harvested and pooled for 
each group. Pooled splenocytes (5 × 105/well) were plated in triplicate into 
96-well plates with medium containing 5% fetal calf serum, l-glutamine, 
antibiotics, and a final concentration of 10 μg/ml LST or variants (or 1% 
DMSO as a control). After 72 hours of incubation, wells were pulsed with 
1 μCi of [3H]thymidine (Dupont NEN, Boston, MA) and harvested 6 hours 
later onto Unifilter 96-well GF/C plates for assessment of thymidine incor-
poration by scintillation counting (Packard MicroSant NXT counter). Serum 
from immunized mice was assayed by ELISA for anti-lysostaphin IgM and 
IgG antibody titers, but no significant anti-lysostaphin antibody signal could 
be detected in either wild type or variant immunized groups. This lack of a 
significant humoral immune response to protein antigens is a well-known 
limitation in BLT mice.66
Transgenic DR4 murine immunogenicity studies
Twelve female 6–8-week-old DR4 transgenic mice (Abb Knockout/Transgenic 
HLA-DR4;  B6.129S2-H2-Ab1tm1GruTg(HLA-DRA/H2-Ea,HLA-DRB1*0401/
H2-Eb)1Kito; Taconic Farms, Germantown, NY) were divided into four groups 
of three each and immunized with 50 μl subcutaneous injections of wild-type 
LST using one of the following four schemes: (i) initial immunization with 100 
μg enzyme in CFA, followed by 100 μg boosts in incomplete Freund’s adjuvant 
(IFA) on days 14 and 28; (ii) initial immunization with 20 μg enzyme in CFA, 
followed by 20 μg boosts in IFA on days 14 and 28; (iii) initial immunization 
with 100 μg enzyme in PBS buffer, followed by 100 μg boosts in PBS buffer 
on days 7, 14, 21, and 28; (iv) initial immunization with 20 μg enzyme in PBS 
buffer, followed by 20 μg boosts in PBS buffer on days 7, 14, 21, and 28. Serum 
IgG antibody titers against wild-type LST were measured on days 13, 20, 27, 
34, and 62. Five weeks after the final boost, all 12 mice exhibited equivalent 
maximum ELISA signals at a 1:40 serum dilution and all signals were within 
20% at a 1:160 dilution (Supplementary Figure S5). Mice were housed without 
further manipulation until week 23 of the study, at which time serum IgG anti-
body titers were again measured and mice were divided into two experimen-
tal arms having equivalent average antibody titers (Supplementary Figure S4). 
Note that during the week 9 to week 23 recovery period, two mice (the lowest 
titer 100 μg no adjuvant and one of the high titer 100 μg adjuvant) began 
suffering hair loss, weight loss, and reduced mobility and were sacrificed as 
per the IACUC approved protocol. At week 24, one arm was rechallenged with 
100 μg wild-type LST in IFA and the other arm with 100 μg variant F4a in IFC. 
At week 26, mice were sacrificed and splenocytes were harvested and pooled 
for each group. Proliferation assays were conducted as described above. Anti-
lysostaphin antibody titers remained high at the end of the 19-week wash-
out period just prior to the final restimulation (average EC50 at week 24 was 
between 1:2,000 and 1:4,000 serum dilution; see Supplementary Figure S4a). 
Thus, the memory immune response could not be readily quantified using 
antibody titers, and instead the ex vivo proliferative response of mouse sple-
nocytes was used to assess the memory immune response against wild type 
LST and the F4a variant.
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